Real-world evidence of the burden of sickle cell disease: a 5-year longitudinal study at a Brazilian reference center

被引:1
|
作者
Barros, Gisele dos Santos [1 ]
Leal, Carla Vaneska Fernandes [1 ]
Leite, Lauro Augusto Caetano [1 ]
Fujimoto, Denys Eiti [1 ]
Cancado, Rodolfo Delfini [1 ]
机构
[1] Fac Ciencias Med Santa Casa Sao Paulo, Rua Marques de Itu,579, Sao Paulo, SP, Brazil
关键词
Sickle cell disease; Vaso-occlusive crises; Public healthcare resources; Brazil;
D O I
10.1016/j.htct.2023.10.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Sickle cell disease (SCD) is an inherited and multisystem blood disorder characterized by hemolytic anemia, vaso-occlusive crises (VOCs), progressive multiorgan damage and increased mortality. In Brazil, it is one of the most common monogenic diseases afflicting 60,000 to 100,000 individuals, however, there are sparse epidemiological data, as well as information on the utilization of public healthcare resources. Method: This was a 5-year (2016 - 2020) retrospective study conducted at one Brazilian reference center on SCD - Santa Results: Among a total of 100 eligible adult patients, the median age was 31.0 years old, 84% of the patients were aged between 18 and 45 years old; 59% were women and 91% presented the genotype HbSS. The number of hematologist and non-hematologist visits at the outpatient unit were 2,198 and 1,436, respectively. The number of hospital ER visits was 758, of which 51% required 864 days of hospitalization. The main cause for seeking hospital medical care was the VOCs. The numbers and ratios of VOCs were: 1 to 10 VOCs, 64%; 11 to 20, 15%, and; 21 or more, 1%. There was a statistically significant difference between the number of VOCs and hospitalizations, as well as infection. Conclusion: Results indicate the burden of SCD on Brazilian patients' daily lives, the impact of VOCs on public healthcare resources, the importance of having a national surveillance program to improve resource utilization and clinical outcomes of patients with SCD and the urgent need for the revitalizing of the current national comprehensive SCD care programs. (c) 2023 Associa & ccedil;& atilde;o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Espa & ntilde;a, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:161 / 166
页数:6
相关论文
共 50 条
  • [21] REAL-WORLD CRIZANLIZUMAB TREATMENT PATTERNS OF PATIENTS WITH SICKLE CELL DISEASE
    Yen, G.
    Yasuda, M.
    McGuiness, C.
    He, J.
    Lee, S.
    Paulose, J.
    Chen, C. C.
    VALUE IN HEALTH, 2022, 25 (07) : S491 - S491
  • [22] Real-world experience of patients with sickle cell disease treated with crizanlizumab
    Chan, Kok Hoe
    Buddharaju, Ruhi
    Idowu, Modupe
    JOURNAL OF INVESTIGATIVE MEDICINE, 2024, 72 (02) : 242 - 247
  • [23] Voxelotor use in adults with sickle cell disease in a real-world setting
    Curtis, Susanna A.
    Betancourt, Jaime
    Kottapalli, Niharika
    Campbell, Sean
    Minniti, Caterina
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (03) : E125 - E128
  • [24] Real-world data on voxelotor to treat patients with sickle cell disease
    Muschick, Kathryn
    Fuqua, Tranaka
    Stoker-Postier, Carrianne
    Anderson, Alan R.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2022, 109 (02) : 154 - 161
  • [25] Mepolizumab for Treatment of Severe Eosinophilic Asthma: A 5-Year Real-World Experience
    Loli-Ausejo, D.
    Perdomo, G.
    Mascaro, B.
    Martinez-Olondris, P.
    Sanchez-Fernandez, M. C.
    Mullol, J.
    Valero, A.
    Arismendi, E.
    Bobolea, I
    JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, 2023, 33 (03) : 209 - 210
  • [26] Disease burden and treatment sequence of polymyositis and dermatomyositis patients in Japan: a real-world evidence study
    Celine Miyazaki
    Yutaka Ishii
    Natalia M. Stelmaszuk
    Clinical Rheumatology, 2022, 41 : 741 - 755
  • [27] Disease burden and treatment sequence of polymyositis and dermatomyositis patients in Japan: a real-world evidence study
    Miyazaki, Celine
    Ishii, Yukata
    Stelmaszuk, Natalia M.
    CLINICAL RHEUMATOLOGY, 2022, 41 (03) : 741 - 755
  • [28] Real-World Experience of Patients With Sickle Cell Disease Treated With Voxelotor: A Multicenter, Retrospective Study
    Andemariam, Biree
    Osunkwo, Ifeyinwa
    Idowu, Modupe
    Shah, Nirmish
    Drachtman, Richard
    Sharma, Archana
    Glaros, Alexander
    Achebe, Maureen
    Nero, Alecia
    Curtis, Susanna
    Minniti, Caterina
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 134 - 135
  • [29] Real-World Experience of Patients with Sickle Cell Disease Treated with Voxelotor: A Multicenter, Retrospective Study
    Andemariam, Biree
    Achebe, Maureen
    Clay, E. Leila Jerome
    Drachtman, Richard A.
    Sharma, Archana
    Nero, Alecia C.
    Osunkwo, Ifeyinwa
    Sarnaik, Sharada
    Idowu, Modupe
    Shah, Nirmish
    Curtis, Susanna A.
    Minniti, Caterina
    BLOOD, 2021, 138
  • [30] The Increased Burden of Sickle Cell Disease in Italy: Findings from the Greatalys (Generating Real world Evidence Across ITALy In SCD) Study
    Franceschi, Luciade
    Forni, Gian Luca
    Castiglioni, Chiara
    Condorelli, Claudia
    Valsecchi, Diletta
    Premoli, Eleonora
    Perrone, Valentina
    Degli Esposti, Luca
    Fiocchi, Carina Andrea
    BLOOD, 2021, 138 : 1950 - +